SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CoTherix (CTRX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (5)3/22/2005 2:29:30 PM
From: tuck  Respond to of 18
 
Links regarding diagnosis and treatment of PAH:

The quick and dirty version:

aafp.org

This entire supplement of Chest appears to be a full text freebie now:

chestjournal.org

It contains many relevant articles; the one on medical treatment mentions Ventavis' competitors.

Edit: here's another one from Circulation: "Future Directions in PAH." It seems to imply that earlier diagnosis isn't going to happen soon. With the symptoms being fairly subtle and easily mistaken for something else, I don't see Ventavis reaching more than those 15,000 patients.

nhlbi.nih.gov

Cheers, Tuck



To: tuck who wrote (5)3/22/2005 2:55:09 PM
From: rkrw  Read Replies (1) | Respond to of 18
 
I think you hit on the main concern, is this a viable product? Can ventavis alone carry ctrx?

Your price assumption is way low. I think remodoulin/flolan sell for upwards of $100K per patient. I'm not sure what ventavis is being priced at but I'd assume closer to $50K. Reaching 3000 patients is no given however. uthr has around 1000, I think, after several years.

ctrx looks very cheap but I'm concerned about its viability as a one product company.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News